Online citations, reference lists, and bibliographies.
← Back to Search

Extended-release Formulations Of Oxybutynin And Tolterodine Exhibit Similar Central Nervous System Tolerability Profiles: A Subanalysis Of Data From The OPERA Trial.

F. Chu, R. Dmochowski, D. Lama, Rodney U. Anderson, P. Sand
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE This study was undertaken to compare the central nervous system (CNS) tolerability profiles of the extended-release formulations of oxybutynin chloride and tolterodine tartrate in the treatment of women with overactive bladder (OAB), as observed in the OPERA (Overactive bladder: Performance of Extended Release Agents) trial. STUDY DESIGN The OPERA trial was a randomized, double-blind, active-control comparison of the efficacy and safety of extended-release oxybutynin (10 mg/d) and extended-release tolterodine (4 mg/d) given to 790 women with OAB for 12 weeks. The incidence of reported CNS events was compared between the treatment groups by using the Fisher exact test. RESULTS The incidence of CNS adverse events was 9% and 8% for the oxybutynin and tolterodine treatment groups, respectively. The difference between groups was not statistically significant. All reported CNS adverse events were rated as mild or moderate in severity. There were no serious treatment-related adverse events in either group, and discontinuation because of a CNS adverse event was infrequent. CONCLUSION The extended-release formulations of oxybutynin and tolterodine were observed to be associated with a similar low incidence of CNS adverse events, which were mostly mild or moderate in severity.
This paper references
The mechanism of action of topiramate
P. N. Patsalos (1999)
10.1093/MILMED/151.1.386
Goodman and Gilman's the Pharmacological Basis of Therapeutics
W. Stigelman (1986)
10.1046/j.1442-2042.2002.00460.x
Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder
J. Lee (2002)
10.1067/MOB.2001.116371
Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
M. A. Harvey (2001)
10.1016/S0022-5347(05)66326-4
Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
J. Malone-Lee (2001)
10.1016/S0029-7844(99)00661-4
Dry Mouth With Conventional and Controlled‐Release Oxybutynin in Urinary Incontinence
E. Versi (2000)
10.1001/ARCHINTE.163.22.2716
Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.
D. Fick (2003)
10.1007/s00345-003-0321-8
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability
M. Halaška (2003)
10.2165/00002018-200225120-00004
A Benefit-Risk Assessment of Extended-Release Oxybutynin
M. Michel (2002)
10.1001/ARCHINTE.1997.00440350031003
Explicit criteria for determining potentially inappropriate medication use by the elderly. An update.
M. Beers (1997)
10.1016/S0149-2918(00)88316-2
An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
M. Goldenberg (1999)
10.1016/S0149-2918(01)80024-2
A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate.
M. Chancellor (2001)
10.1177/009127009903900313
Pharmacokinetics of an Oral Once‐a‐Day Controlled‐Release Oxybutynin Formulation Compared with Immediate‐Release Oxybutynin
S. Gupta (1999)
10.1007/s001929970003
Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder
H. Drutz (1999)
10.1046/J.1464-410X.1998.00717.X
Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder
Abrams (1998)
10.4065/76.4.358
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
R. Appell (2001)
10.2165/00044011-200323060-00003
Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers
K. Diefenbach (2003)
10.3390/60300142
Muscarinic Receptor Agonists and Antagonists
K. Broadley (2001)
10.4065/78.6.687
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
A. Diokno (2003)
10.1007/BF00191165
Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers
A. Pietzko (2004)
Goodman & Gilman's The Pharmacological Basis of Therapeutics
M. Leider (1985)
10.1177/00912700122010528
Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System
A. Todorova (2001)
10.1016/S0022-5347(05)64115-8
Therapeutic Efficacy Of Extended Release Oxybutynin Chloride, And Immediate Release And Long Acting Tolterodine Tartrate In Children With Diurnal Urinary Incontinence
Y. Reinberg (2003)
10.1046/j.1464-410X.2002.02905.x
A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder
H. Y. Leung (2002)
10.1111/j.1532-5415.1998.tb01006.x
Identification of Medications That Cause Cognitive Impairment in Older People: The Case of Oxybutynin Chloride
I. Katz (1998)



This paper is referenced by
10.1007/s11934-004-0068-9
Confusion about measuring central nervous system effects
H. Madersbacher (2004)
Oxybutynin: an overview of the available formulations
R. McCrery (2006)
10.1111/j.1442-2042.2008.02109.x
Dementia and lower urinary dysfunction: With a reference to anticholinergic use in elderly population
R. Sakakibara (2008)
10.1002/jcph.890
Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3‐Year Follow‐up Study
S. Chung (2017)
10.1016/J.UCL.2006.06.003
Oxybutynin in detrusor overactivity.
A. Diokno (2006)
10.1016/j.eururo.2018.10.006
Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
H. Mitcheson (2019)
Drug Class Review: Agents for Overactive Bladder
M. McDonagh (2009)
10.1016/B978-1-4160-6911-9.00076-1
Geriatric Incontinence and Voiding Dysfunction
Neil M. Resnick (2012)
AÞIRI AKTÝF MESANELÝ HASTALARDA ANTÝMUSKARÝNÝK ÝLAÇLARIN ETKÝNLÝÐÝ VE TOLERABÝLÝTESÝ: DERLEME EFFECTIVENESS AND TOLERABILITY OF ANTIMUSCARINIC AGENTS IN PATIENTS WITH OVERACTIVE BLADDER: A REVIEW
Kurtuluþ Kaya (2008)
10.1016/j.juro.2009.06.049
Sacral nerve stimulation for refractory overactive bladder in the elderly population.
W. White (2009)
10.1016/J.AMJMED.2005.12.014
Management of overactive bladder and urge urinary incontinence in the elderly patient.
N. Erdem (2006)
10.1016/j.juro.2008.08.030
Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population.
W. White (2008)
10.1007/BF03058866
Hetzelfde CZS-bijwerkingenprofiel voor vertraagde-afgiftepreparaten oxybutynine en tolterodine
T. Y. Liem (2006)
10.2147/OAJU.S7232
Update on tolterodine extended-release for treatment of overactive bladder
Tola B. Omotosho (2010)
10.1517/14656560903167965
Tolterodine extended-release for overactive bladder
D. Chung (2009)
10.7326/0003-4819-156-12-201206190-00436
Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women
T. Shamliyan (2012)
10.1016/J.AMJMED.2005.12.011
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.
D. Staskin (2006)
10.1038/sj.bjp.0706780
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
P. Abrams (2006)
10.1016/S0378-6080(08)00013-5
13 Drugs that affect autonomic functions or the extrapyramidal system
M. Schachter (2007)
10.23970/AHRQEPCCER212
Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update
E. Balk (2018)
10.1007/s00192-006-0229-0
Current and future trends in the management of overactive bladder
A. Wagg (2006)
10.4137/CMU.S6425
Clinical Use of Tolterodine Extended Release in Overactive Bladder
Oussama El Yazami Adli (2012)
10.2165/11592790-000000000-00000
Safety and Tolerability Profiles of Anticholinergic Agents Used for the Treatment of Overactive Bladder
M. Oefelein (2011)
10.1007/S11884-007-0028-6
Confusion about measuring central nervous system effects
H. Madersbacher (2007)
10.1016/j.juro.2011.05.077
Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
T. Gomes (2011)
10.1016/J.JAMDA.2006.09.011
The application of evidence-based principles of care in older persons (issue 6): urinary incontinence.
B. Zarowitz (2007)
10.1016/J.GERINURSE.2006.08.004
Management of urinary incontinence in older persons.
B. Zarowitz (2006)
10.1111/luts.12018
Depression, Anxiety and the Bladder
R. Sakakibara (2013)
10.12688/f1000research.12593.1
Recent advances in pharmacological management of urinary incontinence
Bronagh M. McDonnell (2017)
10.1185/03007995.2012.709837
An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study
Lorne Aaron (2012)
10.3390/pharmaceutics8030027
Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
Rajan Rajabalaya (2016)
10.4081/ni.2012.e13
Vascular incontinence: incontinence in the elderly due to ischemic white matter changes
R. Sakakibara (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar